Dr. Daniel Lin, Chief of Urologic Oncology, discusses the recent controversy about PSA screening for colon cancer, following negative recommendations by the United States Preventative Services Task Force (USPSTF). Dr. Lin feels it was a premature recommendation to stop PSA screening, but rather should have called for no automatic or routine PSA screening in every man. He believes the decision should be made on an individual basis between a man and his doctor, based on his personal situation and risk factors. Dr. Lin does recognize points in the USPSTS study that have merit, including the concern of over treating men with low-grade or slow-growing tumors. He feels it is important to unlink diagnosis with treatment, and learn to screen smarter such as with less frequency, by developing new biomarkers and embracing active surveillance over treatment in about half of the cases. Dr. Lin also discusses some of the issues with the two major screening trials that he feels skewed the results.